Date: 2013-07-15
Type of information: Licensing agreement
Compound: five medical products based on the MAVIREX® technology platform (antiviral nasal sprays against common cold, influenza and colds in children, antiviral lozenges and a throat spray against viral throat infections)
Company: Marinomed Biotechnologie (Austria) undisclosed international pharmaceutical company
Therapeutic area: Infectious diseases - Respiratory diseases
Type agreement: licensing
Action mechanism:
Disease: respiratory infections
Details: * On July 15, 2013, the Viennese biotech company Marinomed Biotechnologie GmbH announced the closing of a deal for the introduction of its current product portfolio in China today. As part of the new partnership, a major international pharmaceuticals company headquartered in Europe will receive exclusive rights to a whole series of antiviral therapies against respiratory infections. Two of these products – lozenges and a throat spray – are effective against viral throat infections. Both are the newest products in Marinomed\'s growing portfolio. In addition, three nasal sprays, are now also introduced in China for the first time: a spray against common cold, which is already approved in 41 countries, a spray against influenza (approved in 31 countries) and a spray against colds in children (approved in 31 countries).
The details of the agreement that have been released show that, alongside rights for the marketing of Marinomed\'s current cold remedy portfolio, the pharmaceutical partner has also received the production rights. The production is based on know-how of the MAVIREX® technology platform from Marinomed. This technology allows the development of therapies against more than 200 different respiratory virus strains on the basis of natural substances derived from red algae.
Financial terms:
Latest news:
